Amedisys (NASDAQ:AMED) Earns “Neutral” Rating from Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their neutral rating on shares of Amedisys (NASDAQ:AMED) in a research report sent to investors on Thursday morning, Benzinga reports. They currently have a $101.00 target price on the health services provider’s stock.

AMED has been the topic of several other research reports. StockNews.com started coverage on shares of Amedisys in a research report on Monday, April 8th. They issued a buy rating on the stock. Raymond James restated a market perform rating on shares of Amedisys in a research report on Tuesday, March 26th. Finally, Royal Bank of Canada boosted their price objective on shares of Amedisys from $97.00 to $100.00 and gave the company an outperform rating in a research report on Monday, March 25th. Eight investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of Hold and a consensus target price of $97.50.

Amedisys Price Performance

AMED stock opened at $91.79 on Thursday. The company’s fifty day moving average price is $92.54 and its 200-day moving average price is $93.35. Amedisys has a one year low of $73.10 and a one year high of $96.44. The company has a market capitalization of $3.00 billion, a PE ratio of -143.42, a price-to-earnings-growth ratio of 4.29 and a beta of 0.86. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.05 and a current ratio of 1.05.

Amedisys (NASDAQ:AMED) last announced its quarterly earnings results on Wednesday, April 24th. The health services provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. Amedisys had a negative net margin of 0.91% and a positive return on equity of 13.00%. The company had revenue of $571.41 million for the quarter, compared to analysts’ expectations of $565.38 million. During the same quarter in the previous year, the business posted $1.00 earnings per share. Amedisys’s quarterly revenue was up 2.7% on a year-over-year basis. On average, equities analysts anticipate that Amedisys will post 4.54 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Banque Cantonale Vaudoise bought a new position in shares of Amedisys in the first quarter worth about $60,000. Cetera Trust Company N.A bought a new position in shares of Amedisys in the fourth quarter worth about $215,000. CWM LLC grew its holdings in shares of Amedisys by 40.4% in the fourth quarter. CWM LLC now owns 2,629 shares of the health services provider’s stock worth $250,000 after purchasing an additional 757 shares during the last quarter. Contravisory Investment Management Inc. bought a new position in shares of Amedisys in the fourth quarter worth about $258,000. Finally, Mesirow Institutional Investment Management Inc. grew its holdings in shares of Amedisys by 9.9% in the fourth quarter. Mesirow Institutional Investment Management Inc. now owns 2,844 shares of the health services provider’s stock worth $270,000 after purchasing an additional 257 shares during the last quarter. 94.36% of the stock is currently owned by institutional investors.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.